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Abstract
Objective: Depression and anxiety lead to reduced treatment adherence, poorer
quality of life, and increased care costs amongst cancer patients. Mindfulness‐based
cognitive therapy (MBCT) is an effective treatment, but dropout reduces potential
benefits. Smart‐message reminders can prevent dropout and improve effectiveness.
However, smart‐messaging is untested for MBCT in cancer. This study evaluates
smart‐messaging to reduce dropout and improve effectiveness in MBCT for cancer
patients with depression or anxiety.
Methods: Fifty‐one cancer patients attending MBCT in a psycho‐oncology service
were offered a smart‐messaging intervention, which reminded them of prescribed
between‐session activities. Thirty patients accepted smart‐messaging and 21 did
not. Assessments of depression and anxiety were taken at baseline, session‐by‐
session, and one‐month follow‐up. Logistic regression and multilevel modelling
compared the groups on treatment completion and clinical effectiveness. Fifteen
post‐treatment patient interviews explored smart‐messaging use.
Results: The odds of programme completion were eight times greater for patients
using smart‐messaging compared with non‐users, controlling for age, gender, baseline
depression, and baseline anxiety (OR = 7.79, 95% CI 1.75 to 34.58, p = .007). Smart‐
messaging users also reported greater improvement in depression over the pro-
gramme (B = ‐2.33, SEB = .78, p = .004) when controlling for baseline severity, change
over time, age, and number of sessions attended. There was no difference between
groups in anxiety improvement (B = ‐1.46, SEB = .86, p = .097). In interviews, smart‐
messaging was described as a motivating reminder and source of personal connection.
Conclusions: Smart‐messaging may be an easily integrated telehealth intervention
to improve MBCT for cancer patients.
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1 | BACKGROUND
Cancer patients are at three times the risk of depression and anxiety
during and after their treatment.1,2 Depression and anxiety lead to
reduced effectiveness of and adherence to cancer therapies, poorer
quality of life and significantly increased cancer care costs.3,4
Mindfulness‐based cognitive therapy (MBCT) is a well‐evidenced
treatment for depression and anxiety among cancer patients.5-13 This
group‐based programme teaches participants to purposefully attend
to their experiences in the moment, just as they are, without judge-
ment.5,14 This philosophy can be helpful for cancer patients dealing
with difficulties and uncertainties around their current or future
health. However, MBCT requires substantial prescribed home practice
activities between sessions and non‐adherence can lead to poorer
outcomes.15 Furthermore, dropout rates in recent trials of
mindfulness‐based group interventions in cancer have ranged from
21% to 35%,16-18 which is higher than for group psychological thera-
pies in general.19-21 The problem may be particularly acute amongst
cancer patients because of physical limitations and ongoing treatment.
However, an eHealth enhancement could be used to improve the
situation.
Current evidence suggests that brief, easily‐implemented
reminders, such as targeted text‐messages, can reduce non‐attendance
and improve health behaviour‐change.22-24 “Smart‐messaging” inter-
ventions like this have been shown to improve physical and mental
health among cancer patients.25 Yet, smart‐messaging has not been
used for MBCT in cancer, despite evidence that smart‐messaging is
one of the easiest and most cost‐effective telehealth interventions to
integrate within routine care.22,26,27
This study aimed to evaluate the use of a smart‐messaging inter-
vention to reduce dropout and improve effectiveness of MBCT for
cancer patients with depression and anxiety. The study also aimed to
evaluate the effectiveness of MBCT for cancer patients in a routine
care setting.
2 | METHOD
2.1 | Design
A mixed‐methods proof of concept evaluation was used to offer ini-
tial assessment of smart‐messaging's effectiveness in MBCT for can-
cer. The study also explored potential mechanisms of change. The
smart‐messaging reminder intervention + MBCT was compared with
MBCT alone. Smart‐messaging was added to six consecutive groups
of MBCT run between November 2015 and July 2018 for cancer
and palliative care patients who were referred to a UK psycho‐
oncology service. Each patient was offered the choice of receiving
smart‐messaging reminders during MBCT or not. Users and non‐
users were compared on MBCT completion rate and clinical out-
comes, controlling for baseline severity and key demographic
characteristics.
2.2 | Participants
Participants were receiving cancer treatment from an NHS hospital or
palliative care from a hospice and had been referred to the embedded
psycho‐oncology service. All 51 patients who attended one or more
sessions of MBCT were included in the study*. Thirty patients chose
to receive smart messaging during the programme and 21 patients
did not. Patients were told that they did not need to give a reason
for their choice and were not asked why they declined to avoid clini-
cian coercion. Fifteen participants took part in post‐treatment inter-
view; those who had not used smart‐messaging were then asked
about reasons for declining.
2.3 | Procedure
All patients were referred to psycho‐oncology by healthcare
professionals from their cancer care team, including oncologists, sur-
geons, radiologists, cancer nurse specialists, and allied healthcare
professionals.
Patients were assessed by a clinical psychologist and accepted into
MBCT if at least mild‐to‐moderate clinical anxiety and/or depression
symptoms were identified using standardized assessments. Patients
were included if their overall health status suggested that they would
be able to attend and participate for the full duration of the pro-
gramme. If patients were too unwell for the programme they were
offered one‐to‐one psychological support. At initial assessment the
commitments required during the programme were described. This
included the commitment to carry out home practice mindfulness
exercises for 40 minutes six days‐a‐week between sessions and
attend all sessions (two planned omissions were accepted, as many
patients still required several other treatment appointments). If
patients were unable to meet these commitments, they were not
included in an MBCT programme, but offered a different psychological
therapy. In total 283 patients were referred to the psycho‐oncology
service in the study period and 76 (27%) patients were assessed as
suitable for the MBCT programme. The 25 who did not attend any
sessions of MBCT withdrew primarily for health‐related limitations
(e.g. feeling too fatigued, 10/52) or for practical reasons (e.g. unable
to commit to programme dates or times 6/25). The remainder either
experienced spontaneous remission prior to the group starting and
opted out (4/25) or gave no reason (5/25).
At initial assessment, the smart‐messaging reminder intervention
was explained to all patients. Written informed consent was then
sought from patients who agreed to use smart‐messaging, ensuring
patients understood that:
1. The system was automated (without a real person to respond in
case of emergency)
2. Anonymized messaging data would be used for evaluation
3. They could stop the messages at any time
The care offered to those who opted‐out of receiving smart‐
messages was not changed in any other way.
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Standardized, self‐reported pre‐group outcome assessments were
completed by patients between one and four weeks prior to the start
of MBCT. Assessments were then completed prior to each MBCT ses-
sion, including one‐month follow‐up. Session attendance was
recorded on a patient register maintained by the programme leaders.
Unique identifiers were used on the smart‐messaging system
instead of names to maintain anonymity. The system stored data on
patients' use of smart‐messaging, which was linked to the appropriate
patients using a key to the unique identifiers stored securely by the
psycho‐oncology service. Demographic and clinical details were
extracted from patients' clinical records and compiled on an
anonymized database.
All patients were invited to take part in a 15‐minute telephone
interview about their experiences of MBCT including questions about
their experience of smart‐messaging (e.g. “How did you find the text‐
messages you received as part of the programme?”). Those who
declined to use smart‐messaging were asked about their reasons for
opting‐out. Interviewees gave written informed consent for the
interview to be recorded, transcribed verbatim and the contents anon-
ymously reported. Fifteen‐minute telephone interviews were com-
pleted in the two weeks after the one‐month follow‐up session by
research assistants and students who were not involved in leading
the MBCT programme. Interviewers were trained in semi‐structured
interview technique and were familiar with an interview guide used
to focus the interview on key areas of interest.
2.4 | Outcome measures
Programme completion was the primary study outcome. Programme
completion has previously been defined as attending four or more
MBCT sessions, because this has been observed to be the adequate
treatment dose for clinical effects.28 Programme completers were
defined in this way for analysis. Session attendance was defined
attending any part of an MBCT session, even if late. Attendance was
recorded by MBCT therapists.
Symptom improvements were secondary outcomes. The nine‐item
Patient Health Questionnaire (PHQ‐9) measures symptoms of depres-
sion based on diagnostic criteria for major depression. The PHQ‐9 has
excellent test‐retest reliability (α = .84) and good convergent validity
with general mental health assessment (r = .73).29
The seven‐item Generalized Anxiety Disorder scale (GAD‐7) is a
measure of generalized anxiety symptoms based on diagnostic criteria.
It has excellent test‐retest reliability (ICC = .83) and good convergent
validity with other anxiety measures (rs = .72 to.74).30
2.5 | Interventions
2.5.1 | MBCT
During MBCT participants are trained to use mindfulness skills to
address problems related to ruminative thinking patterns known to
maintain anxiety and depression.5 The programme particularly focuses
on the use of non‐judgemental, present moment awareness to make
purposeful choices about self‐management of physical and emotional
health.5,31 Each session involves reviewing activities carried out
between sessions; introducing new mindfulness practices; exploring
in‐session experiences, and psychoeducation based on cognitive ther-
apy32 around the role of mindfulness in everyday life. The programme
runs for eight weekly sessions with an additional one‐month follow‐
up session. An adapted version of the MBCT programme was used to
address the needs of cancer patients.31 The cancer‐adapted version
ofMBCT closely follows the original programme, but makes explicit ref-
erence to common problems associated with cancer and its treatment.
2.5.2 | Smart‐messaging
The “Florence” eHealth system (www.simple.uk.net) was used to pro-
vide MBCT attendees with text‐messages to support their attendance
and engagement. Florence would send a text‐message the day after
the MBCT session reminding participants of the home practice for
the week:
Hi, it's Jo & Sam†. This is a reminder of the week's
home practice: Body scan, routine activity, the pause,
eating mindfully. Text Y for more.
Patients receiving the text could then request up to four further
texts by replying with “Y” which offered more detail on the initial text:
Hi, it's Jo & Sam. The body scan is about allowing things
to be as they are without trying to changethem. Text Y
for more.
Two days later the Florence system sent a reminder of the theme
for the previous session:
Hi, it's Jo & Sam. This is a reminder of the theme from
week 1 – we looked at the impact of being on
automatic pilot. Text Y for more.
Again, at patients' choice they could receive no further messages
or request up to four further reminders which added more detail:
Hi, it's Jo & Sam. On automatic pilot we are more likely
to react out of habit which often means we are
stressed more easily. Text Y for more.
Lastly, patients were sent a reminder about the following session
on the day before the group was due to meet:
Hi, it's Jo & Sam. This is a reminder that we are meeting
tomorrow morning, so today is the last opportunity to
practice! Text Y for more.
Patients received a minimum of three text‐messages per week but
could request an additional nine if they wished.
2.6 | Therapists
The MBCT therapists were trained using a national programme which
included attending an MBCT programme, leading assessed MBCT
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sessions, leading an initial staff MBCT programme, and monthly super-
vision with an experienced MBCT therapist.
2.7 | Method of analysis
The overall clinical effectiveness of MBCT was evaluated using paired
t‐tests comparing baseline depression (PHQ‐9) and anxiety (GAD‐7)
with one‐month follow‐up. Cohen's d33 was calculated for a standard-
ized effect size.
Patient characteristics were compared between smart‐messaging
users and non‐users. Categorical variables were compared using chi
square and continuous variables using Mann‐Whitney U.
The comparative odds ratio for MBCT completion was calculated
using a logistic regression with MBCT completion as a dichotomous
outcome whilst controlling for age, gender, baseline depression and
baseline anxiety.
To account for the repeated measurement design, multilevel
modelling was used to assess differences between smart‐message
users and non‐users in anxiety and depressive symptoms over time.
Multilevel modelling allows data to be nested hierarchically. In this
case, repeated measurements of depression or anxiety (level 1: time
hereafter) were nested within the individual patients who gave those
measurements (level 2). Multilevel modelling therefore accounts for
covariance of depressive symptoms occurring within participants and
between participants compared with more typical regression
methods.34 Covariance within participants accounted for 79% of total
covariance. Established model‐building guidelines were used to
develop the multilevel analysis.35 The hierarchical structure of data
was examined in unconditional models, then model fit was explored
using ‐2 log likelihood. Random intercepts and slopes were included
for time and a diagonal covariance matrix was used. Parameter estima-
tion was made using maximum likelihood. When depression (PHQ‐9)
was the outcome, the fully adjusted model included the following
fixed‐effect covariates at the patient level: time (adjusting for ordered
change over time); baseline PHQ‐9 score (adjusting for baseline depres-
sion severity); number of sessions attended (adjusting for MBCT dos-
age); and age (controlling for demographic differences in engagement
with smart‐messaging). A parallel model was applied to examine anxi-
ety (GAD‐7) as the outcome variable: The same model development
methods and covariates were repeated but assessing whether use of
smart‐messaging predicted anxiety.
As data were collected from routine care, sample size could not be
manipulated. However, the sample size exceeded the minimum
recommended for both multilevel modelling and logistic regression
(minimum n of 50 at level 2 in multilevel modelling and minimum n
of 10 per parameter in regression analyses36,37;). Missing data were
not imputed, only observed values were used in analysis.
Semi‐structured interviews were analysed by first extracting dis-
cussion of smart‐messaging from interview transcripts then using the-
matic analysis.38 This included making initial notations, followed by
grouping notations into themes and then structuring these themes
as succinctly, coherently and meaningfully as possible. An independent
review of the analysis was carried out by one author who had not
been involved in data collection or initial analysis (SM), to enhance
the quality and dependability of findings.
Ethical approval was not required, as the study used anonymized
data collected as part of routine care. The study was registered with
the host NHS Trust.
3 | RESULTS
3.1 | Patient characteristics
The majority of patients were women (84%), with breast cancer being
the most common cancer site (49%). The patients who chose to use
smart messaging were significantly younger than non‐users (mean
age = 54 versus 59; Z = 2.12, p = .034). Smart‐messaging users also
attended more sessions (mean = 6 versus 4; Z = 3.55, p<.001). These
factors were entered as covariates in models comparing the clinical
effectiveness of the two groups. Smart‐messaging users did not differ
from non‐users on any other characteristics (Table S1).
3.2 | MBCT completion rate
The odds of MBCT completion (attending four or more sessions) were
eight times higher for smart‐messaging users than non‐users, when
controlling for age, gender, baseline depression and baseline anxiety
(OR = 7.79, 95% CI 1.75 to 34.58, p = .007; Table 1). Twenty‐six
smart‐messaging users (87%) completed MBCT compared with eight
non‐users (38%).
3.3 | Overall effectiveness
Paired t‐tests indicated a significant reduction in symptoms of depres-
sion (PHQ‐9: M = ‐4.7, SD = 4.6; t(27) = 5.59, p < .001) and anxiety
(GAD‐7: M = ‐4.6, SD = 5.7; t(26) = .88, p = .001) from baseline to
one‐month post‐treatment. This suggests a large pre‐post effect size
for depression (d = .8) and anxiety (d = .9). There were also trends
for stepwise improvements in symptoms as more MBCT sessions
were attended (Figure 1).
TABLE 1 Smart‐messaging use as a predictor of MBCT completion
Predictor
variable B SE Wald p
Adjusted
OR 95% CI
Age ‐0.03 0.04 0.67 .437 0.97 0.91 1.04
Gender 1.04 1.13 0.85 .413 0.97 0.90 1.04
Baseline
depression
(PHQ‐9)
‐0.08 0.09 0.69 .357 2.82 0.31 25.65
Baseline anxiety
(GAD‐7)
‐0.06 0.10 0.43 .407 0.93 0.78 1.11
Smart‐messaging
use
2.05 0.76 7.28 .007 7.79 1.75 34.58
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Figure 1. Depression (PHQ‐9) and anxiety (GAD‐7) scores over
time
3.4 | Differential effectiveness
Smart‐messaging users showed significantly reductions in symptoms
of depression over the MBCT programme compared with non‐users
(Table 2). Depression scores (PHQ‐9) reduced by 2.3 points (95% CI:
0.76 – 3.89) more amongst smart‐messaging users, when controlling
for baseline severity, age, number of sessions attended, and covari-
ance over time. Smart‐messaging users did not differ significantly from
non‐users on changes in anxiety, but there was a trend for greater
improvement (B = ‐1.46, SE B = .86, p = .097).
3.5 | Smart‐messaging engagement
Smart‐messaging users requested further messages 14 times on aver-
age during MBCT (SD = 16; range = 0–50, a total of 63 messages could
have been requested).
3.6 | Patient interviews (n=15)
Two patients were interviewed who had opted not to use smart‐
messaging. Both explained that confidence in the use of mobile
phones had prevented them from using it:
I don't really read messages on my phone or anything
like that [] sometimes I don't really understand it fully
so, and I don't like to ask 'cos I feel daft, if you know
what I mean, it's like you should know everything
apparently according to my kids anyway. I should be
in the know about everything about computers and
all that, and I'm not so.
(Group 5; patient D)
From interviews with 13 patients who used smart‐messaging, one
theme was represented in all interviews: smart‐messaging as a prompt
and reminder:
Yes, I thought [smart‐messaging] was a good idea, they
reminded you [] they prompted you to think: “Yes, I'll
do that”. (Group 2, patient A)
In some cases the reminding effect was also motivating:
FIGURE 1 Depression and anxiety scores
over time
TABLE 2 Smart‐messaging use as a predictor of depression change over time
Fixed effects Random effects
95% CI
Parameter B SE p Lower Bound Upper Bound Parameter Variance SE z p
Intercept 5.06 2.65 0.062 ‐0.27 10.38 Residual variance 6.64 0.60 11.08 0.000
Assessment time point ‐0.67 0.10 0.000 ‐0.87 ‐0.47 Intercept variance 1.62 1.09 1.49 0.137
Baseline depression (PHQ‐9) 0.87 0.06 0.000 0.74 0.99 Slope variance 0.27 0.09 2.99 0.003
Number of sessions attended 0.23 0.17 0.173 ‐0.10 0.56
Age ‐0.04 0.03 0.265 ‐0.10 0.03
Smart‐messaging use ‐2.33 0.78 0.004 ‐3.89 ‐0.76
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I thought they were good, erm it sort of motivated you
and was a gentle reminder really, yeah. So I thought
that that was a good idea. (Group 5, patient F)
In other cases, the reminding effect was seen to draw participants
back to mindfulness practice:
[Smart‐messages] were good reminders. If you found
yourself getting lost they were good reminders to put
you back on track. Because at the beginning as I say it
feels more like homework, you don't feel like you're
getting anything from it at the beginning. So it's about
putting it into life and doing it and then you get out
what you've put into it [] but you don't at first you
just think it's homework. (Group 1, patient H)
These quotes suggest the effect of smart‐messaging may be to
increase motivation and help MBCT attendees stay “on track” by
incorporating mindfulness exercises into their daily lives, particularly
during the early phases of the programme when they may not have
experienced benefits from home practice. However, a secondary
theme of personal connection indicated that for some patients (4/13)
smart messaging had more than a reminding effect:
When you got it you felt “oh somebody is thinking
about me.” Even though it was just a text‐message, if
that makes sense. (Group 1, patient I)
Interestingly, the personal connection was still reported even in full
acknowledgement that messages were not personally sent:
You felt like, I mean I know they were automated, but
in a silly way it felt like somebody was motivating you.
I enjoyed them actually. (Group 1, patient D)
These quotes imply that some patients felt a connection to a
person, in spite of knowing that the messages were automated. This
sense of personal connection again appeared to play a role in motivat-
ing patients to do mindfulness home practice.
One patient reported irritation from smart‐messaging:
I kept getting [text‐messages] I think it needs to be
sorted out a bit better. (Group 5, patient A)
4 | DISCUSSION
This paper presents a proof of concept evaluation for a smart‐
messaging enhancement to MBCT, pragmatically assessed in routine
care. Results suggest that those using smart‐messaging have signifi-
cantly better completion rates and improvements in depressive symp-
toms. This study can inform effect and sample size estimates for a
future RCT to evaluate clinical efficacy. Among patients who tried
the intervention, there are indications of feasibility and acceptability.
However, 41% chose not to receive the intervention. Interview
data offer an exploratory view of possible mechanisms for the effect
of smart‐messaging. Patients predominantly reported that smart‐
messages acted as a prompt and reminder, which motivated them to
carry out home practice at times when they may not have experienced
benefits from this discipline. However, some also reported a more per-
sonal connection through the messages they received which further
motivated home practice. It is plausible that those who committed to
more home practice were less likely to dropout. Overall, this study
suggests that integrating smart‐messages about MBCT content is a
promising, cheap method worthy of further investigation in improving
clinical effectiveness and efficiency.
4.1 | Relationship to existing research
This study supports existing evidence that relatively brief, low‐
intensity behavioural reminders may lead to significant changes in
health‐related behaviour amongst cancer patients.25 Yet, this appears
to be the first application of smart‐messaging technology to MBCT for
cancer patients. The current study adds that MBCT benefits may be
enhanced by integrating messaging‐based reminders of MBCT teach-
ing and practices. This study's pragmatic, service‐level, choice‐based
design offers findings that are reflective of clinical practice and may
therefore be more generalizable. Interviews also illuminated possible
causal explanations from patients' personal experience.
4.2 | Study limitations
Uncontrolled group allocation means that the findings reported remain
tentative, because selection bias could mean there were unmeasured
differences between groups. For example, there was no baseline mea-
sure of patient motivation when greater motivation might explain
patients choosing to use smart‐messaging, improved completion rates
and better outcomes. Nonetheless, several key baseline characteristics
were controlled in the analysis.
Despite giving a service‐level impression of the impact smart‐
messaging may have in a psycho‐oncology setting, this study can give
little specific information for patients from individual cancer sites,
stages or treatment types. Therefore, questions remain about the
differential impact of smart‐messaging between cancer types.
4.3 | Future research
Current findings require evaluation within an RCT, including assess-
ment of home practice to evaluate whether smart‐messaging leads
to an associated increase in this potential mediator. The smart‐
messaging method could be enhanced in future by sending more indi-
vidualized messages, which can increase the impact.39
4.4 | Clinical implications
Although more focus is given to remote delivery and computerized
versions of psychological therapies in psycho‐oncology, this study sug-
gests that existing treatments may be enhanced quickly and cheaply
without additional therapist input. Specifically, smart‐messaging is an
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accessible and easily integrated intervention that may enhance treat-
ment effectiveness and adherence, but can be overlooked as old or
peripheral technology. This study suggests smart‐messaging could be
a means of enhancing MBCT in psycho‐oncology.
5 | CONCLUSION
The effectiveness and efficiency of MBCT may be enhanced by inte-
grating smart‐messaging through the programme.
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